Viamet Pharmaceuticals
Morrisville
About Viamet Pharmaceuticals
Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophile™ Technology. Viamet's disruptive Metallophile™ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $120.1M
- Funding stage: M&A
- Last round: Series Unknown (Aug 2022)
- Website: viamet.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Medical Device, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/viamet-pharmaceuticals-142050 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.